Form 4: Alnylam CSO Kevin Fitzgerald Reports Stock Sales Following PSU Vesting

Alnylam CSO Kevin Fitzgerald reports the sale of company stock to cover tax obligations after a performance-based stock unit (PSU) vested due to positive clinical trial results.

Summary

• Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reported transactions involving Alnylam common stock.
• On June 24, 2024, Fitzgerald was granted 2,498 shares of common stock upon vesting of a performance-based stock unit (PSU) related to a Phase 3 clinical study.
• On June 25, 2024, Fitzgerald sold a total of 970 shares of common stock at prices ranging from $221.71 to $235.73 per share.
• These sales were executed to cover minimum statutory tax withholding obligations resulting from the PSU vesting.
• Following these transactions, Fitzgerald directly owns 14,181 shares and indirectly owns 537 shares through a managed account.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of the PSU is a positive event, indicating progress in clinical trials. However, the subsequent stock sales are a routine event and don't necessarily reflect a change in the executive's confidence in the company.

Positives

• The vesting of the PSU indicates the achievement of a significant performance milestone related to a Phase 3 clinical study, suggesting positive progress in Alnylam's drug development pipeline.
• The positive clinical trial results triggered the vesting of the PSU, which is a positive indicator for the company's research and development efforts.

Industry Context

This filing is typical for corporate executives who receive stock-based compensation. The sale of shares to cover tax obligations is a common practice. The vesting of the PSU is tied to clinical trial success, which is a key driver for pharmaceutical company valuations.

Comparison to Industry Standards

• Stock sales by executives are a common occurrence in publicly traded companies, especially after vesting events.
• Companies like Ionis Pharmaceuticals and Arrowhead Pharmaceuticals, which also focus on RNA therapeutics, see similar patterns of insider transactions related to stock options and awards.
• The amount of stock sold is relatively small compared to the total outstanding shares of Alnylam, suggesting it's unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal.
• Employees may view the vesting of the PSU as a positive sign of the company's progress and success.

Key Dates